NewEdge Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

NewEdge Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$766K	Sell	2,316 -701	-23%	-$239K	﹤0.01%	1667
2025 Q4	$1.2M	Buy	3,017 +1,493	+98%	+$661K	﹤0.01%	1376
2025 Q3	$695K	Buy	1,524 +820	+116%	+$334K	﹤0.01%	1619
2025 Q2	$229K	Buy	704 +703	+70,300%	+$195K	﹤0.01%	2153
2025 Q1	$270	Sell	1 -972	-100%	-$250K	﹤0.01%	3778
2024 Q4	$229K	Buy	973 +972	+97,200%	+$256K	﹤0.01%	2021
2024 Q3	$275	Sell	1 -994	-100%	-$259K	﹤0.01%	3662
2024 Q2	$242K	Buy	995 +977	+5,428%	+$154K	﹤0.01%	1828
2024 Q1	$2.69K	Buy	18 +14	+350%	+$2.33K	﹤0.01%	3314
2023 Q4	$765	Hold	4	–	–	﹤0.01%	3497
2023 Q3	$708	Hold	4	–	–	﹤0.01%	3215
2023 Q2	$760	Hold	4	–	–	﹤0.01%	3281
2023 Q1	$801	Sell	4 -60	-94%	-$12.6K	﹤0.01%	3187
2022 Q4	$13.8K	Buy	+64	New	+$13.7K	﹤0.01%	2263

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewEdge Advisors's ALNY Position: Q1 2026 in Review

NewEdge Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 23% in Q1 2026, selling an estimated $239K and leaving 2,316 shares worth $766K. The position accounts for ﹤0.01% of the portfolio, ranked #1667.

NewEdge Advisors first reported a position in ALNY in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.2M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

NewEdge Advisors held 2,316 shares of Alnylam Pharmaceuticals worth $766K as of Q1 2026.
NewEdge Advisors sold 701 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $239K.
Alnylam Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #1667 holding.
NewEdge Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
NewEdge Advisors's Alnylam Pharmaceuticals position peaked at $1.2M in Q4 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.